JP2022105069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022105069A5 JP2022105069A5 JP2022070352A JP2022070352A JP2022105069A5 JP 2022105069 A5 JP2022105069 A5 JP 2022105069A5 JP 2022070352 A JP2022070352 A JP 2022070352A JP 2022070352 A JP2022070352 A JP 2022070352A JP 2022105069 A5 JP2022105069 A5 JP 2022105069A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptides
- neoantigen
- subject
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 89
- 102000004196 processed proteins & peptides Human genes 0.000 claims 83
- 239000000203 mixture Substances 0.000 claims 51
- 230000035772 mutation Effects 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 21
- 238000000034 method Methods 0.000 claims 18
- 208000035269 cancer or benign tumor Diseases 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 12
- 230000001613 neoplastic effect Effects 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 229960005486 vaccine Drugs 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000012648 POLY-ICLC Substances 0.000 claims 6
- 230000005867 T cell response Effects 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 230000003308 immunostimulating effect Effects 0.000 claims 6
- 239000003018 immunosuppressive agent Substances 0.000 claims 6
- 108700002563 poly ICLC Proteins 0.000 claims 6
- 229940115270 poly iclc Drugs 0.000 claims 6
- 229950010550 resiquimod Drugs 0.000 claims 6
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 108700028369 Alleles Proteins 0.000 claims 4
- 108010026552 Proteome Proteins 0.000 claims 4
- -1 SRL172 Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims 4
- 230000006698 induction Effects 0.000 claims 4
- 238000012163 sequencing technique Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 229920002498 Beta-glucan Polymers 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- GUVMFDICMFQHSZ-UHFFFAOYSA-N N-(1-aminoethenyl)-1-[4-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[hydroxy-[[3-[hydroxy-[[3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-[[[2-[[[2-[[[5-(2-amino-6-oxo-1H-purin-9-yl)-2-[[[5-(4-amino-2-oxopyrimidin-1-yl)-2-[[hydroxy-[2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-3-yl]oxy-hydroxyphosphinothioyl]oxymethyl]oxolan-2-yl]-5-methylimidazole-4-carboxamide Chemical compound CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 GUVMFDICMFQHSZ-UHFFFAOYSA-N 0.000 claims 3
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 229940056913 eftilagimod alfa Drugs 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 229960002751 imiquimod Drugs 0.000 claims 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 239000011859 microparticle Substances 0.000 claims 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 229950008737 vadimezan Drugs 0.000 claims 3
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 239000000277 virosome Substances 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 230000000947 anti-immunosuppressive effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940029030 dendritic cell vaccine Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061873A JP2025106390A (ja) | 2013-04-07 | 2025-04-03 | 個別化された新生物ワクチンの組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809406P | 2013-04-07 | 2013-04-07 | |
| US61/809,406 | 2013-04-07 | ||
| US201361869721P | 2013-08-25 | 2013-08-25 | |
| US61/869,721 | 2013-08-25 | ||
| JP2020000367A JP7489193B2 (ja) | 2013-04-07 | 2020-01-06 | 個別化された新生物ワクチンの組成物及び方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000367A Division JP7489193B2 (ja) | 2013-04-07 | 2020-01-06 | 個別化された新生物ワクチンの組成物及び方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061873A Division JP2025106390A (ja) | 2013-04-07 | 2025-04-03 | 個別化された新生物ワクチンの組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022105069A JP2022105069A (ja) | 2022-07-12 |
| JP2022105069A5 true JP2022105069A5 (enExample) | 2022-08-03 |
Family
ID=50842334
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507587A Active JP6702855B2 (ja) | 2013-04-07 | 2014-04-07 | 個別化された新生物ワクチンの組成物及び方法 |
| JP2020000367A Active JP7489193B2 (ja) | 2013-04-07 | 2020-01-06 | 個別化された新生物ワクチンの組成物及び方法 |
| JP2022070352A Pending JP2022105069A (ja) | 2013-04-07 | 2022-04-21 | 個別化された新生物ワクチンの組成物及び方法 |
| JP2025061873A Pending JP2025106390A (ja) | 2013-04-07 | 2025-04-03 | 個別化された新生物ワクチンの組成物及び方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507587A Active JP6702855B2 (ja) | 2013-04-07 | 2014-04-07 | 個別化された新生物ワクチンの組成物及び方法 |
| JP2020000367A Active JP7489193B2 (ja) | 2013-04-07 | 2020-01-06 | 個別化された新生物ワクチンの組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061873A Pending JP2025106390A (ja) | 2013-04-07 | 2025-04-03 | 個別化された新生物ワクチンの組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160101170A1 (enExample) |
| EP (1) | EP2983702A2 (enExample) |
| JP (4) | JP6702855B2 (enExample) |
| KR (3) | KR102341899B1 (enExample) |
| CN (4) | CN118557711A (enExample) |
| AU (5) | AU2014251207B2 (enExample) |
| BR (1) | BR112015025460B1 (enExample) |
| CA (2) | CA2908434C (enExample) |
| IL (2) | IL241858B (enExample) |
| WO (1) | WO2014168874A2 (enExample) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| MX360823B (es) | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| JP6484558B2 (ja) | 2012-11-28 | 2019-03-13 | バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ | 癌ワクチンの組み合せ物 |
| CA2908434C (en) * | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| NZ721105A (en) * | 2013-12-06 | 2022-04-29 | Broad Inst Inc | Formulations for neoplasia vaccines |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3194970B1 (en) | 2014-09-10 | 2021-07-28 | F. Hoffmann-La Roche AG | Immunogenic mutant peptide screening platform |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016100977A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Methods for profiling the t-cel- receptor repertoire |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| WO2016123365A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of Michigan | Liposomal particles comprising biological molecules and uses thereof |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3268012A4 (en) * | 2015-03-12 | 2018-10-31 | Health Research, Inc. | Enrichment of cd16+ monocytes to improve dendritic cell vaccine quality |
| EP3273944B1 (en) | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| EP3075389A1 (en) * | 2015-03-31 | 2016-10-05 | Technische Universität München | T cell receptors and peptides derived by mutations for the treatment of cancer |
| US20190099475A1 (en) | 2015-04-08 | 2019-04-04 | Nantomics, Llc | Cancer neoepitopes |
| WO2016172722A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CA2982266A1 (en) * | 2015-04-27 | 2016-11-03 | Nicholas MCGRANAHAN | Method for treating cancer |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| IL293135A (en) | 2015-05-13 | 2022-07-01 | Agenus Inc | Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide |
| CR20200476A (es) * | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
| TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| US12150980B2 (en) | 2015-07-30 | 2024-11-26 | Modernatx, Inc. | Concatemeric peptide epitope RNAs |
| GB201516047D0 (en) * | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| JP2018532736A (ja) | 2015-10-12 | 2018-11-08 | ナントミクス，エルエルシー | チェックポイント阻害物質への感受性を予測するｍｓｉおよびネオエピトープの探索のための系、組成物、および方法 |
| US11623001B2 (en) * | 2015-10-12 | 2023-04-11 | Nantomics, Llc | Compositions and methods for viral cancer neoepitopes |
| JP2018535202A (ja) | 2015-10-12 | 2018-11-29 | ナントミクス，エルエルシー | ネオエピトープの反復発見と適応可能な免疫療法およびその方法 |
| MX387275B (es) * | 2015-10-12 | 2025-03-18 | Nantomics Llc | Neoepítopos virales y sus usos |
| TWI733719B (zh) | 2015-12-07 | 2021-07-21 | 美商河谷控股Ｉｐ有限責任公司 | 改善的組合物及用於新表位之病毒遞送的方法及其應用 |
| CN108601731A (zh) * | 2015-12-16 | 2018-09-28 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| JP2019509265A (ja) * | 2016-02-11 | 2019-04-04 | ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ | 二重標的化によるアデノウイルスの皮下送達 |
| EP3414692A4 (en) * | 2016-02-12 | 2020-07-29 | Nantomics, LLC | HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES |
| WO2017222619A2 (en) | 2016-03-24 | 2017-12-28 | Nantcell, Inc. | Sequence arrangements and sequences for neoepitope presentation |
| EP3446119A1 (en) * | 2016-04-18 | 2019-02-27 | The Broad Institute Inc. | Improved hla epitope prediction |
| EP3452082A1 (en) | 2016-05-04 | 2019-03-13 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| EA201990071A1 (ru) | 2016-06-20 | 2019-06-28 | АйЭсЭй ФАРМАСЬЮТИКАЛЗ Б.В. | Композиция пептидной вакцины |
| PL3488443T3 (pl) * | 2016-07-20 | 2021-12-20 | BioNTech SE | Selekcja neoepitopów jako swoistych dla choroby celów dla terapii o zwiększonej skuteczności |
| US10350280B2 (en) | 2016-08-31 | 2019-07-16 | Medgenome Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
| EP3535423B1 (en) * | 2016-11-07 | 2022-01-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Methods for selecting therapy for a cancer patient |
| AU2017363308B2 (en) * | 2016-11-23 | 2024-08-08 | Seattle Project Corp. | Viral delivery of neoantigens |
| CN110214275B (zh) * | 2016-12-01 | 2022-12-06 | 南托米克斯有限责任公司 | 肿瘤抗原性加工和呈递 |
| WO2018140391A1 (en) | 2017-01-24 | 2018-08-02 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JP7155470B2 (ja) * | 2017-03-31 | 2022-10-19 | エーシーティー ジェノミックス （アイピー） カンパニー リミテッド | 免疫原性がん特異的エピトープのためのランク付けシステム |
| WO2018183544A1 (en) * | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Method for identification of retained intron tumor neoantigens from patient transcriptome |
| WO2018195357A1 (en) * | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| WO2018200389A1 (en) * | 2017-04-24 | 2018-11-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US20200276285A1 (en) | 2017-06-02 | 2020-09-03 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| CN110720127A (zh) * | 2017-06-09 | 2020-01-21 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| KR102684237B1 (ko) * | 2017-06-21 | 2024-07-11 | 트랜스진 | 개인 맞춤형 백신 |
| AU2018287169B2 (en) * | 2017-06-22 | 2024-11-14 | Neogap Therapeutics Ab | T-cell expansion method and uses |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| JP7763588B2 (ja) * | 2017-09-05 | 2025-11-04 | グリットストーン バイオ インコーポレイテッド | Ｔ細胞療法用の新生抗原の特定法 |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| EP3688165A4 (en) * | 2017-09-25 | 2021-09-29 | Nant Holdings IP, LLC | VALIDATION OF THE PRESENTATION OF NEOEPITOPES |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| US11779599B2 (en) | 2017-11-07 | 2023-10-10 | Coimmune, Inc. | Methods and uses for dendritic cell therapy |
| EP3714275A4 (en) * | 2017-11-22 | 2021-10-27 | Gritstone bio, Inc. | REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS |
| WO2019105485A1 (zh) * | 2017-12-01 | 2019-06-06 | 上海桀蒙生物技术有限公司 | 个性化癌症疫苗的制备方法 |
| WO2019122050A1 (en) | 2017-12-22 | 2019-06-27 | Isa Pharmaceuticals B.V. | Methods of immunization |
| CN108491689B (zh) * | 2018-02-01 | 2019-07-09 | 杭州纽安津生物科技有限公司 | 基于转录组的肿瘤新抗原鉴定方法 |
| JP2021522239A (ja) | 2018-04-26 | 2021-08-30 | アジェナス インコーポレイテッド | 熱ショックタンパク質結合ペプチド組成物およびその使用方法 |
| MX2020012649A (es) * | 2018-05-25 | 2021-07-02 | The Wistar Inst | Neoantígenos especificos de tumor y métodos de uso de estos. |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3813848A4 (en) * | 2018-06-27 | 2022-07-20 | ModernaTX, Inc. | Personalized cancer vaccine epitope selection |
| WO2020020444A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
| EP3826669A2 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| CA3109430A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN112771214B (zh) | 2018-09-27 | 2025-06-13 | 耐考德治疗股份有限公司 | 用于选择新表位的方法 |
| CN109337873A (zh) * | 2018-09-30 | 2019-02-15 | 北京鼎成肽源生物技术有限公司 | 一种lrff细胞 |
| JP2022506839A (ja) * | 2018-11-07 | 2022-01-17 | モデルナティエックス インコーポレイテッド | Ｒｎａがんワクチン |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| GB201821207D0 (en) | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| AU2020232971A1 (en) * | 2019-03-01 | 2021-09-23 | Scott R. BURKHOLZ | Design, manufacture, and use of personalized cancer vaccines |
| EP3935638B1 (en) * | 2019-03-08 | 2025-11-05 | Nantomics, LLC | System and method for variant calling |
| CN110059625B (zh) * | 2019-04-18 | 2023-04-07 | 重庆大学 | 一种基于mixup的人脸训练与识别方法 |
| JP2022533861A (ja) * | 2019-05-03 | 2022-07-26 | ギレム リチャード | がんにおける新抗原 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| EP3983008A4 (en) * | 2019-06-11 | 2023-07-12 | Iogenetics, LLC. | IMMUNOTHERAPIES BASED ON NEO-ANTIGENS |
| EP3987028A4 (en) * | 2019-06-21 | 2023-07-19 | Kernal Biologics, Inc. | MODIFIED ONCOSELECTIVE PROTEIN EXPRESSION |
| CN110514845B (zh) * | 2019-08-22 | 2022-09-27 | 深圳新合睿恩生物医疗科技有限公司 | 一种肿瘤新生抗原免疫原性检测方法及检测平台 |
| CN116688107A (zh) * | 2019-09-06 | 2023-09-05 | 北京微九九科技有限公司 | 一种肿瘤疫苗的制备方法及使用该方法制备的肿瘤疫苗 |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| WO2021092436A1 (en) * | 2019-11-08 | 2021-05-14 | The Regents Of The University Of California | Identification of splicing-derived antigens for treating cancer |
| JP7496111B2 (ja) * | 2019-12-24 | 2024-06-06 | 国立大学法人東京工業大学 | サブキャリア変調方式テラヘルツレーダー |
| US11011253B1 (en) * | 2020-07-09 | 2021-05-18 | Brian Hie | Escape profiling for therapeutic and vaccine development |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| EP4255474A4 (en) * | 2020-12-07 | 2025-06-18 | Iogenetics, LLC. | PERSONALIZED IMMUNOTHERAPIES |
| US20240024439A1 (en) * | 2020-12-07 | 2024-01-25 | Iogenetics, Llc | Administration of anti-tumor vaccines |
| GB202104715D0 (en) | 2021-04-01 | 2021-05-19 | Achilles Therapeutics Uk Ltd | Identification of clonal neoantigens and uses thereof |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| CN113069537A (zh) * | 2021-04-29 | 2021-07-06 | 江苏欣生元生物科技有限公司 | 一种基于ras变异新生抗原表位的融合蛋白纳米疫苗及其制备方法 |
| CN117321189A (zh) | 2021-04-30 | 2023-12-29 | 泰根制药有限公司 | 淋巴细胞的单血管扩增 |
| CN112972666B (zh) * | 2021-05-12 | 2021-08-31 | 山东兴瑞生物科技有限公司 | 个性化基因修饰肿瘤dc疫苗的制备方法 |
| US20220383996A1 (en) * | 2021-05-27 | 2022-12-01 | Amazon Technologies, Inc. | Assigning peptides to peptide groups for vaccine development |
| WO2023043888A1 (en) * | 2021-09-15 | 2023-03-23 | Celloram Inc. | Method of treating cancer |
| TW202340474A (zh) | 2022-01-11 | 2023-10-16 | 大陸商深圳市珈鈺生物科技有限公司 | 樹突細胞腫瘤疫苗和其用途 |
| CA3253072A1 (en) * | 2022-05-11 | 2023-11-16 | Fundacao D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Centro De Investig Da | METHOD FOR PREPARING AND MULTIPLYING AN IMMUNE CELL POPULATION FOR CANCER THERAPY, BIOLOGICAL ACTIVITY TEST FOR TUMOR RECOGNITION, PREPARATION OF BIOLOGICAL VACCINES AND EPITOPE TARGET FOR ANTIBODIES |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| WO2024097864A1 (en) | 2022-11-02 | 2024-05-10 | Tigen Pharma Sa | Expansion of lymphocytes |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| CN120600110B (zh) * | 2025-08-06 | 2025-12-09 | 上海交通大学医学院附属仁济医院 | 基于人工智能的多变病原t细胞表位精准筛选方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
| US4210644A (en) | 1978-02-23 | 1980-07-01 | The Johns Hopkins University | Male contraception |
| US4226859A (en) | 1979-06-07 | 1980-10-07 | Velsicol Chemical Corporation | Pyridyl esters of N-alkylidene-substituted phosphor- and phosphonamidic acids |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| EP0188040B1 (en) | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
| US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
| US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4816540A (en) | 1987-06-12 | 1989-03-28 | Yasuhiko Onishi | Cationic graft-copolymer |
| US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US5035891A (en) | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| DE69031305T2 (de) | 1989-11-03 | 1998-03-26 | Univ Vanderbilt | Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5198223A (en) | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| KR100501022B1 (ko) | 1998-07-28 | 2005-07-18 | 다나베 세이야꾸 가부시키가이샤 | 장내 적소 방출형 제제 |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| CA2651796A1 (en) * | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
| EP2127671B1 (en) * | 2007-02-07 | 2016-09-14 | Nec Corporation | Therapeutic agent for cancer |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| US8900600B2 (en) * | 2009-04-02 | 2014-12-02 | Vaxon Biotech | Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy |
| KR102315754B1 (ko) * | 2010-05-14 | 2021-10-22 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| MX360823B (es) * | 2011-05-24 | 2018-11-16 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacunas individualizadas para el cancer. |
| CN104662171B (zh) * | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
| CA2908434C (en) * | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
-
2014
- 2014-04-07 CA CA2908434A patent/CA2908434C/en active Active
- 2014-04-07 AU AU2014251207A patent/AU2014251207B2/en active Active
- 2014-04-07 BR BR112015025460-8A patent/BR112015025460B1/pt active IP Right Grant
- 2014-04-07 WO PCT/US2014/033185 patent/WO2014168874A2/en not_active Ceased
- 2014-04-07 KR KR1020157031939A patent/KR102341899B1/ko active Active
- 2014-04-07 JP JP2016507587A patent/JP6702855B2/ja active Active
- 2014-04-07 EP EP14727288.4A patent/EP2983702A2/en active Pending
- 2014-04-07 CA CA3137846A patent/CA3137846A1/en active Pending
- 2014-04-07 CN CN202410556851.8A patent/CN118557711A/zh active Pending
- 2014-04-07 CN CN202410556757.2A patent/CN118750591A/zh active Pending
- 2014-04-07 CN CN202311507937.3A patent/CN117815373A/zh active Pending
- 2014-04-07 CN CN201480032291.0A patent/CN105377292A/zh active Pending
- 2014-04-07 KR KR1020217041186A patent/KR20210156320A/ko not_active Ceased
- 2014-04-07 KR KR1020237034437A patent/KR102858313B1/ko active Active
-
2015
- 2015-10-06 IL IL241858A patent/IL241858B/en active IP Right Grant
- 2015-10-07 US US14/877,125 patent/US20160101170A1/en not_active Abandoned
-
2019
- 2019-05-24 AU AU2019203664A patent/AU2019203664B2/en active Active
- 2019-05-24 AU AU2019203665A patent/AU2019203665B2/en active Active
-
2020
- 2020-01-06 JP JP2020000367A patent/JP7489193B2/ja active Active
- 2020-11-04 US US17/089,408 patent/US20210220455A1/en active Pending
-
2021
- 2021-04-08 IL IL282202A patent/IL282202B2/en unknown
- 2021-11-12 AU AU2021266338A patent/AU2021266338B2/en active Active
-
2022
- 2022-04-21 JP JP2022070352A patent/JP2022105069A/ja active Pending
-
2025
- 2025-02-05 AU AU2025200780A patent/AU2025200780A1/en active Pending
- 2025-04-03 JP JP2025061873A patent/JP2025106390A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022105069A5 (enExample) | ||
| Galli et al. | Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy | |
| Wang et al. | Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy | |
| JP7437939B2 (ja) | 集団に基づいた免疫原性ペプチドの同定のプラットフォーム | |
| JP7229516B2 (ja) | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ | |
| Hunder et al. | Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 | |
| KR102308798B1 (ko) | 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격 | |
| Obara et al. | Present status and future perspective of peptide‐based vaccine therapy for urological cancer | |
| JP2018519243A5 (enExample) | ||
| JP2018529320A5 (enExample) | ||
| CN105418751B (zh) | 来自sparc的癌排斥抗原肽以及含有该肽的药物 | |
| KR20180111998A (ko) | 비호지킨 림프종 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| JP2017502076A5 (enExample) | ||
| IL309003A (en) | Novel peptides, combination of peptides and scaffolds for use in immunothera-peutic treatment of various cancers | |
| JP2023113688A (ja) | 様々ながんに対する免疫療法で使用される新規ペプチドおよびペプチドの組み合わせ | |
| Pollack et al. | Immune‐BasedTherapies for Sarcoma | |
| Lee et al. | Precision medicine-enabled cancer immunotherapy | |
| US20210138053A1 (en) | Anti-tumoral composition | |
| JP2023549342A (ja) | 個別化されたがんワクチンのためのネオアンチゲンの選択 | |
| US20220265792A1 (en) | Methods for treating solid tumors | |
| KR20200040892A (ko) | 알독소루비신 조합 치료 및 방법 (aldoxorubicin combination treatments and methods) | |
| CA2815125C (en) | Her2 dna vaccine as adjunct treatment for cancers in companion animals | |
| Shaik et al. | Tumor infiltration therapy: from FDA approval to next-generation approaches | |
| Smyth et al. | Spatially fractionated x-ray microbeams elicit a more sustained immune and inflammatory response in the brainstem than homogenous irradiation | |
| Shaik | UNVEILING THE HIDDEN REPERTOIRE OF GLIOBLASTOMA TUMOR ANTIGENS BY GENETIC MODOFICATION OF TUMOR CELLS WITH THE MHC CLASS II TRANSACTIVATOR CIITA |